Propuesta de bioterio entomológico de Lucilia Sericata como alternativa biológica para regeneración de tejidos en infecciones crónicas
No hay miniatura disponible
Fecha
2025
Autores
Cassiani Valdes, Luz Karime
Título de la revista
ISSN de la revista
Título del volumen
Editor
Ediciones Universidad Simón Bolívar
Facultad de Ciencias Básicas y Biomédicas
Facultad de Ciencias Básicas y Biomédicas
Resumen
Este proyecto plantea la creación de un Bioterio Entomológico de Larvas (BEL) con fines terapéuticos con Lucilia sericata, para la producción de larvas estériles de uso clínico en la regeneración de tejidos y el tratamiento de heridas crónicas. La propuesta responde a la creciente demanda de alternativas biotecnológicas sostenibles y eficaces frente a infecciones resistentes a los antibióticos como problema de salud pública que aumenta la morbimortalidad por infecciones bacterianas. Ante este panorama, se propone evaluar la instalación de un BEL como innovación biológica para la regeneración tisular en infecciones crónicas, utilizando larvas de Lucilia sericata en terapia larvaria, también conocida como biocirugía, emergiendo como una alternativa sostenible y efectiva. Esta terapia emplea larvas estériles de Lucilia sericata, una especie no hematófaga que cuenta con propiedades terapéuticas bien documentadas. Su método de acción se fundamenta en larvas con habilidad de eliminar tejido necrótico por medio del desbridamiento selectivo que reduce la carga bacteriana mediante la secreción de elementos antimicrobianos promoviendo la regeneración tisular de heridas crónicas, úlceras diabéticas y lesiones infectadas que no responden a la terapia convencional. Para valorar la viabilidad del BEL se utilizó un análisis PESTEL con el fin de detectar los aspectos políticos, económicos, sociales, tecnológicos, ecológicos y jurídicos que afectan la viabilidad del proyecto, una revisión normativa y teórica siguiendo el método PRISMA 2020.
This project proposes the creation of an Entomological Larvae Bioterium (BEL) for therapeutic purposes using Lucilia sericata, to produce sterile larvae for clinical use in tissue regeneration and the treatment of chronic wounds. The proposal responds to the growing demand for sustainable and effective biotechnological alternatives to antibiotic-resistant infections, which are a public health problem that increases morbidity and mortality from bacterial infections. Given this situation, it is proposed to evaluate the installation of a BEL as a biological innovation for tissue regeneration in chronic infections, using Lucilia sericata larvae in larval therapy, also known as biosurgery, which is emerging as a sustainable and effective alternative. This therapy uses sterile larvae of Lucilia sericata, a non-hematophagous species with well-documented therapeutic properties. Its method of action is based on larvae with the ability to remove necrotic tissue through selective debridement, which reduces the bacterial load by secreting antimicrobial elements, promoting tissue regeneration in chronic wounds, diabetic ulcers, and infected lesions that do not respond to conventional therapy. To assess the viability of BEL, a PESTEL analysis was used to identify the political, economic, social, technological, environmental, and legal aspects that affect the viability of the project, along with a regulatory and theoretical review following the PRISMA 2020 method
This project proposes the creation of an Entomological Larvae Bioterium (BEL) for therapeutic purposes using Lucilia sericata, to produce sterile larvae for clinical use in tissue regeneration and the treatment of chronic wounds. The proposal responds to the growing demand for sustainable and effective biotechnological alternatives to antibiotic-resistant infections, which are a public health problem that increases morbidity and mortality from bacterial infections. Given this situation, it is proposed to evaluate the installation of a BEL as a biological innovation for tissue regeneration in chronic infections, using Lucilia sericata larvae in larval therapy, also known as biosurgery, which is emerging as a sustainable and effective alternative. This therapy uses sterile larvae of Lucilia sericata, a non-hematophagous species with well-documented therapeutic properties. Its method of action is based on larvae with the ability to remove necrotic tissue through selective debridement, which reduces the bacterial load by secreting antimicrobial elements, promoting tissue regeneration in chronic wounds, diabetic ulcers, and infected lesions that do not respond to conventional therapy. To assess the viability of BEL, a PESTEL analysis was used to identify the political, economic, social, technological, environmental, and legal aspects that affect the viability of the project, along with a regulatory and theoretical review following the PRISMA 2020 method
Descripción
Palabras clave
Resistencia a los antimicrobianos, Terapia larvaria, Lucilia sericata, Desbridamiento biológico, Regeneración tisular
